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Background
Autism spectrum disorder is a heritable developmental disorder in which chromo-
somal abnormalities are thought to play a role. 
Methods
As a first component of a genomewide association study of families from the Au-
tism Genetic Resource Exchange (AGRE), we used two novel algorithms to search 
for recurrent copy-number variations in genotype data from 751 multiplex families 
with autism. Specific recurrent de novo events were further evaluated in clinical-
testing data from Children’s Hospital Boston and in a large population study in 
Iceland.
Results
Among the AGRE families, we observed five instances of a de novo deletion of 593 
kb on chromosome 16p11.2. Using comparative genomic hybridization, we ob-
served the identical deletion in 5 of 512 children referred to Children’s Hospital 
Boston for developmental delay, mental retardation, or suspected autism spectrum 
disorder, as well as in 3 of 299 persons with autism in an Icelandic population; the 
deletion was also carried by 2 of 18,834 unscreened Icelandic control subjects. The 
reciprocal duplication of this region occurred in 7 affected persons in AGRE fami-
lies and 4 of the 512 children from Children’s Hospital Boston. The duplication also 
appeared to be a high-penetrance risk factor.
Conclusions
We have identified a novel, recurrent microdeletion and a reciprocal microduplication 
that carry substantial susceptibility to autism and appear to account for approxi-
mately 1% of cases. We did not identify other regions with similar aggregations of 
large de novo mutations.
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A 
utism is a pervasive developmental 
disorder  defined  by  a  neurobehavioral 
phenotype that includes social disability, 
communication  impairment,  repetitive  behav-
iors, and restricted interests. The onset is gener-
ally before the age of 3 years, and the disorder 
has a prevalence of 0.6% in the population, af-
fecting many more boys than girls.1 Results of 
twin and family studies have shown that the her-
itability of autism is approximately 90%, making 
it one of the most heritable complex disorders.2 
In approximately 10% of patients, autism can be 
explained  by  genetic  syndromes  and  known 
chromosomal  anomalies  (most  of  which  have 
recognizable features in addition to autism), in-
cluding the fragile X syndrome, tuberous sclero-
sis, the Smith–Lemli–Opitz syndrome, the Po-
tocki–Lupski syndrome, and maternally inherited 
duplications of the region (15q11–13) that is af-
fected in the Prader–Willi and Angelman syn-
dromes.2 However, despite the high heritability 
of autism, genetic studies have not provided sub-
stantial insight into the 90% of cases of autism 
whose cause is idiopathic.
The relative genetic contribution to a suscep-
tibility to autism from de novo mutations, rare 
mutations,  and  common  polymorphisms  has 
been debated extensively.3 Recent whole-genome 
studies  assessing  copy-number  variation4  re-
ported an excess of large de novo copy-number 
variants, with such events reported in 7 to 10% 
of simplex families, 2 to 3% of multiplex fami-
lies, and only 1% of control families.5,6 Although 
these data imply a role for de novo copy-number 
variation,  no  recurrent  events  were  identified 
and implicated as having an unequivocal asso-
ciation with autism.
We therefore carried out a high-resolution ge-
nomewide  analysis  of  a  sample  of  multiplex 
families  in  the  Autism  Genetic  Resource  Ex-
change (AGRE)7 with the use of the Affymetrix 
5.0 genotyping platform. This platform offers 
not only single-nucleotide polymorphism (SNP) 
probes but also a dense collection of SNP invari-
ant probes, which combine to enable detection of 
copy-number variation. In this study, we describe 
a screening technique for recurrent de novo auto-
somal copy-number variants that could influence 
susceptibility to autism with follow-up analysis of 
clinical genetic-testing data from Children’s Hos-
pital Boston and a large population sample from 
Iceland (studied at deCODE Genetics).
Methods
Study Design
The samples and methods that we used are sum-
marized in Table 1. Detailed materials and meth-
ods describing sample collections and methods 
of copy-number analysis (the copy-number poly-
morphism  evaluation  routine  [COPPER]  and 
Birdseye algorithms) are provided in the Supple-
mentary Appendix, available with the full text of 
this article at www.nejm.org. These novel meth-
ods have good power to detect deletions span-
ning at least 10 probes (approximately 30 kb) on 
the Affymetrix 5.0 platform. We screened AGRE 
samples only from persons without known chro-
mosomal anomalies, the fragile X syndrome, and 
other established syndromes.
The study was approved by the institutional 
review boards at the Massachusetts Institute of 
Technology (for the AGRE samples) and Chil-
dren’s Hospital Boston (for the Children’s Hospi-
tal samples) and by the Data Protection Author-
ity and National Bioethics Committee of Iceland 
(for  the  deCODE  samples).  Written  informed 
consent was obtained from all subjects in the 
AGRE and deCODE research studies. Children’s 
Hospital  Boston  carried  out  comparative  ge-
nomic hybridization for clinical diagnostic pur-
poses;  since  results  were  anonymous  and  ob-
tained by chart review, research-based informed 
consent  was  not  required  by  the  institutional 
review board that approved the study.
Results
Copy-Number Abnormalities
To  discover  recurrent  deletions  or  duplications 
conferring a risk of autism in multiple families, we 
used the COPPER algorithm to identify regions in 
which three or more patients with autism had over-
lapping copy-number (or genomic “dosage”) ab-
normalities — that is, we looked for regions that 
had either fewer than or more than two genomic 
copies. To ensure that these regions were not sites 
of common copy-number polymorphism, we fo-
cused on regions that were variant in less than 1% 
of parents of subjects with autism. For each event 
predicted by COPPER and meeting these criteria, 
we used visual inspection of intensity data, wheth-
er the same event was predicted with Birdseye, and 
analysis of mendelian inheritance to assess our 
confidence in the observation.
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We identified 32 high-confidence regions and 
15 lower-confidence regions, and all but 1 of 
these regions appeared to be normally segregat-
ing variants. Of these regions, 16 (including 8 
with high confidence) had at least one de novo 
event in which both parents were negative for 
the copy-number variant, suggesting the possi-
bility of recurrent mutation. Although the ma-
jority of these variants did not cosegregate with 
autism  (and  probably  constitute  rare,  neutral 
copy-number variations), one region stood out as 
having multiple de novo events and no inherited 
events.
Microdeletion on Chromosome 16p11.2
A region on chromosome 16p11.2 (from genomic 
coordinates 29.5 Mb to 30.1 Mb) was unique in 
our data. Five children (four boys and one girl) 
with autism in four independent families carried 
de novo deletions; we observed no deletions in 
the parents. One pair of siblings who were not 
monozygous  twins  shared  the  de  novo  event, 
presumably inherited from a parent with germ-
line mosaicism. In the children with autism, we 
observed that the 16p11.2 deletion occurred on 
chromosomes derived from both the mother and 
the father.
The region coincides perfectly with a segment 
of 593 kb flanked by a 147-kb segmental dupli-
cation with 99.5% sequence identity. The identi-
fication  of  this  cluster  of  de  novo  events  by 
COPPER was confirmed by analysis of the same 
data  with  the  use  of  Birdseye,  with  perfect 
agreement  in  identification  of  five  samples 
with this deletion (Fig. 1). In addition, three of 
these samples overlapped with subjects who were 
genotyped  at  Johns  Hopkins  with  Affymetrix 
500K chips in an autism sample (provided by the 
National Institute of Mental Health), where the 
same  deletions  were  identified  by  CNAT  4.0 
(Affymetrix). The size of these deletions (593 kb, 
containing 86 distinct sites with SNP or copy-
number probes) generates confidence that this 
observation  is  genuine,  with  all  five  subjects 
having a logarithm of the odds (LOD) of more 
than 50 in favor of a dosage of 1 (i.e., a hemizy-
gous  deletion)  (Table  1  of  the  Supplementary 
Appendix). We did not observe the deletion in 
the parents of these five children (LOD >50 in 
favor of a normal dosage of 2 in all parents), nor 
did we observe it in any of the 1420 parents in 
this study.
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Deletion and normal dosage were positively 
confirmed by multiplex ligation-dependent probe 
amplification (MLPA) for all subjects in all four 
of these AGRE families (Fig. 1C). However, in 
2814 samples from other studies (unpublished 
data), three female control subjects (who par-
ticipated in a study of bipolar disorder but were 
not screened for autism) carried the deletion (see 
the Supplementary Appendix). The deletion rate 
in this population is much lower than the rate in 
the sample of children with autism (P = 0.03 for 
the deletion), although it suggests that the dele-
tion does not cause severe autism in every case.
Duplication in Families with Autism
We observed reciprocal duplication of the 593-kb 
deleted region in three AGRE families (with at 
least one family member with a LOD >30) (Fig. 
1). This duplication was inherited in two fami-
lies: it was transmitted from a parent to two of 
two affected offspring (male and female) as well 
as to one unaffected daughter and from another 
parent to four of four affected sons. In the third 
family, the duplication appeared to be a de novo 
event in one of two affected male offspring. The 
full duplication was not observed in any of the 
2814 samples from other studies analyzed and 
thus appears to be a high-penetrance risk factor 
conferring risk to seven additional subjects with 
autism in the AGRE sample (P = 1.1×10−4 for both 
deletions and duplications) (Table 1, and Table 1 
of the Supplementary Appendix).
Additional Duplications in AGRE Families
We identified five large duplications of three dif-
ferent sizes in the 15q11–13 region associated 
with the Prader–Willi and Angelman syndromes 
(Table 2). Of these duplications, one was mater-
nally inherited, one occurred in a subject whose 
father had a normal dosage and whose mother 
was unobserved, and three were de novo duplica-
tions; the smallest extended from genomic posi-
tion 23 Mb to 25 Mb on chromosome 15. This 
relatively small duplication could help to focus 
candidate-gene studies since it included only two 
genes — ATP10A and GABRB3.
We did not observe de novo deletion or dupli-
cation of a recently implicated gene, NRXN1 on 
chromosome  2,5,8  although  we  observed  six 
families with deletions within the NRXN1 locus. 
The deletions did not cosegregate with autism in 
four of the six families (i.e., not all affected per-
sons inherited the deletion) and were not associ-
ated with autism on the basis of a transmission 
disequilibrium  test.  We  observed  deletions  at 
this  locus  in  5  of  the  2814  control  samples. 
Other events coincident with regions that were 
highlighted in two recent studies5,6 are listed in 
Table 2 of the Supplementary Appendix.
To  obtain  a  more  complete  tally  of  poten-
tially causal recurrent events, we used the Bird-
seye algorithm to search for de novo deletions 
and duplications of 20 kb or larger in genome-
wide data obtained from the AGRE samples. We 
found no additional de novo events in multiple 
subjects that were not observed in the Interna-
tional HapMap Project or in 2814 samples from 
control subjects. Although we detected approxi-
mately 50 de novo events of more than 100 kb 
that  were  not  seen  in  HapMap,  a  number  of 
these events did not cosegregate with autism in 
other  families  or  they  have  been  observed  in 
samples from subjects who did not have autism; 
all  such  events  require  further  study  in  addi-
tional subjects and much larger control samples 
before those that may confer susceptibility can 
be identified.
Figure 1 (facing page). Regions of Microdeletion  
and Microduplication on Chromosome 16p11.2.
In Panel A, normalized intensity data are averaged ev-
ery 11 to 12 probes across a 2-Mb region on chromo-
some 16. Means (closed circles) and standard devia-
tions (vertical bars) for subjects with normal copy 
numbers are depicted in blue; subjects with duplica-
tion are denoted with red open circles, and those with 
deletions are denoted with green triangles. Annotated 
genes in the region of interest are shown (not to 
scale), with gray denoting brain expression and black 
denoting unknown or little brain expression. Arrows 
represent the segmental duplications mediating the re-
arrangements, with three genes located within the seg-
mental duplication. In Panel B, both the deletion and 
duplication graphs show shifted overlaying of two trac-
es of multiplex ligation-dependent probe amplification 
(MLPA). Red tracings in both graphs represent a nor-
mal control sample. In the deletion graph, blue trac-
ings show a sample with a 16p11.2 deletion; in the du-
plication graph, blue tracings show a sample with a 
16p11.2 duplication. The MLPA profiles were generat-
ed by ABI 3730 Genetic Analyzer and normalized by 
GeneMarker software (SoftGenetics). The four ampli-
cons that are underlined with a black bar and shown 
with arrows are from probes located within the imbal-
anced 16p11.2 region. Amplicons labeled with C are 
control probes located either on chromosome 16 but 
outside the imbalanced region or on other chromo-
somes.
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Confirmation in Clinical Samples
We tested for replication of the association be-
tween the 16p11.2 microdeletion and autism in a 
sample of 512 children with developmental de-
lay, mental retardation, or autism spectrum dis-
order who were identified independently at Chil-
dren’s Hospital Boston with the use of comparative 
genomic hybridization. We identified five addi-
tional 16p11.2 deletions (all in boys, including 
one pair of monozygotic twins); the boundaries 
of the deletion in each case were identical to that 
described above (Fig. 1 and Table 3 of the Supple-
mentary Appendix). One deletion was inherited 
from a mother with mild mental retardation, and 
the rest were de novo.
By contrast, we observed no deletions of this 
region  in  samples  from  434  patients  at  Chil-
dren’s Hospital Boston that were tested by com-
parative genomic hybridization in the same labo-
ratory. Samples from these children were submitted 
for diagnostic testing because they had dysmor-
phic features, multiple congenital anomalies, con-
genital heart disease, seizures, or other pheno-
types  in  which  developmental  delay,  mental 
retardation,  or  autism  spectrum  disorder  was 
not indicated by the ordering physician.
The duplication at 16p11.2 was also observed 
in four independent samples (two from boys and 
two from girls) from the 512 children who were 
tested with the use of array comparative genomic 
hybridization for developmental delay, mental re-
tardation, or autism spectrum disorder; the du-
plication was not observed in any of the 434 chil-
dren who were tested for other diagnoses. This 
finding significantly reinforces the association of 
dosage abnormalities at 16p11.2 and phenotypes 
associated with autism spectrum disorder and de-
velopmental delay (P = 0.007 for both deletions 
and duplications) (Table 1). Clinical features are 
described in Table 4 of the Supplementary Ap-
pendix.  All  deletions  and  duplications  in  this 
sample were positively confirmed with the use 
of MLPA and fluorescence in situ hybridization 
(FISH) (Fig. 1C and 2).
Replication in an Icelandic Sample
We observed that 3 of 299 subjects with autism 
spectrum  disorder  from  Iceland  carried  the 
16p11.2 deletion, a finding that was consistent 
with the 1% frequency observed in children at 
Children’s Hospital Boston who had sporadic de-
velopmental delay or autism spectrum disorder 
(Table 5 of the Supplementary Appendix). One of 
these deletions was de novo, the origin of the 
second deletion was not known, and one was in-
herited from a father who had attention deficit–
hyperactivity disorder (ADHD). By contrast, in a 
control sample of 18,834 subjects who did not 
undergo screening for a psychiatric or language 
disorder, only two deletions were observed — in 
other words, the deletion was observed more of-
ten in patients with autism by a factor of 100 
(P = 3.7×10−5). However, in a study of the same 
population by investigators at deCODE Genetics, 
this  deletion  was  observed  at  a  markedly  in-
creased rate in subjects with a psychiatric or lan-
guage disorder. This study showed that the dele-
tion  was  present  in  1  of  648  patients  with 
schizophrenia, 1 of 420 patients with bipolar dis-
order, 1 of 203 patients with ADHD (the father of 
a child with autism, as noted above), and 1 of 
3000 patients with panic disorder, anxiety, de-
pression, or addiction. In addition, 1 of 748 pa-
tients with dyslexia carried the deletion. Overall, 
in the Icelandic samples, the carrier frequency 
among patients with autism was 1%; the fre-
quency was approximately 0.1% among patients 
with  a  psychiatric  or  language  disorder  and 
0.01% in the general population.
We did not observe the duplication of this 
region in any of the Icelandic subjects with au-
tism spectrum disorder but did observe it in two 
subjects  with  bipolar  disorder  and  five  un-
screened  control  subjects,  with  a  carrier  fre-
quency of 0.04% in subjects with a psychiatric or 
language disorder and in 0.03% of the general 
population.
In total, we have observed the identical dele-
tion of nearly 600 kb in 13 subjects with autism 
Table 2. Duplication of Chromosome 15q11–13 in the AGRE Sample.*
Chromosome and Region  Inheritance and Transmission 
Chromosome 15
21.2–26.3 (BP2–BP3) 2 De novo copy-number variants
18.8–26.4 (BP1–BP3) Inherited copy-number variant, 2 transmit-
ted and 0 not transmitted; 1 unknown
23.3–24.7 De novo copy-number variant 
* Duplications of the region associated with the Prader–Willi and Angelman 
syndromes were detected by applying novel algorithms to Affymetrix 5.0 geno-
type data. For inherited events, listed are the number of transmitted copy-
number variants and the number of copy-number variants that were not trans-
mitted to affected offspring for whom data were available. AGRE denotes 
Autism Genetic Resource Exchange.
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or  developmental  or  language  delay  (10  con-
firmed de novo mutations, 2 confirmed inherit-
ed mutations from parents with ADHD or men-
tal  retardation,  and  1  mutation  of  unknown 
inheritance),  with  the  reciprocal  duplication  of 
the  same  region  documented  in  11  additional 
subjects. The very low frequency (less than 0.1%) 
of dosage abnormalities in this region in the gen-
eral population and the fact that we have yet to 
identify an instance in which the deletion was 
transmitted from an asymptomatic parent indi-
cate strong natural selection, particularly against 
the recurrent microdeletion. A dosage abnormal-
ity in this region was present in 1% of autism 
samples from multiplex families, 1% of subjects 
with autism in a general population sample, and 
more than 1.5% of subjects with a developmental 
or language delay in a clinical setting.
Discussion
We identified regions of rare copy-number varia-
tion in families with autism and observed an as-
sociation between a microdeletion on chromo-
some 16 (and the inherited reciprocal duplication) 
and autism. Both the deletion and the duplication 
are likely to be mediated by the 147-kb segmental 
duplication flanking the deleted or duplicated 
sequence.9  Microdeletion  or  microduplication 
through  intrachromosomal  recombination  be-
tween  segmentally  duplicated  sequences  is  an 
established mechanism associated with congeni-
tal developmental disorders such as the Smith–
Magenis  syndrome,  the  Williams  syndrome,10 
the Potocki–Lupski syndrome (17p11.2 duplica-
tion),11 and the DiGeorge syndrome (22q11 dele-
tion).12  The  deleted  or  duplicated  region  on 
16p11.2 contains 25 annotated genes or tran-
scripts, and the flanking segmental duplications 
include an additional 3 genes (Fig. 1B). Several of 
the genes contained in this region could be con-
sidered good candidates for driving the pheno-
type on the basis of their expression in the brain 
or function in neurodevelopment.
We performed a simple calculation of differ-
ences in carrier frequency in subjects with autism 
and population controls for these events and as-
signed P values for the comparisons, achieving 
statistical significance in all three components 
of the study (the AGRE screening, the Children’s 
Hospital  Boston  replication,  and  the  deCODE 
Icelandic replication). However, such calculations 
underrepresent the full evidence in favor of cau-
sation because they do not reflect the fact that 
most of the deletions are de novo. If this dele-
tion were neutral, the single-generation muta-
tion rate implied by the observation of nine de 
novo events in fewer than 2500 subjects with 
autism would demand that the frequency of the 
deletion itself be extremely high, if not fixed, in 
the  absence  of  very  strong  selective  pressure 
against  it.  The  fact  that  it  is  seen  extremely 
rarely in the general population not only estab-
lishes a significant difference between rates in 
autism and control populations but also unam-
biguously establishes that strong natural selec-
tion is acting against transmission of this dele-
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Figure 2. Analysis with Fluorescence in Situ Hybridization (FISH).
BAC clone RP11-504I2 was used as a probe for FISH analysis. Panel A rep-
resents a cell in metaphase from a normal control in which FISH signals 
(arrows) were detected on a pair of chromosome 16. Panel B represents a 
cell in metaphase from a sample with a 16p11.2 deletion in which a FISH 
signal was seen on one chromosome 16 (arrow) but not on the other chro-
mosome 16 (arrowhead). Panel C shows a cell in interphase from a sample 
with a 16p11.2 duplication in which three FISH signals (arrows) were de-
tected. Panel D shows a cell in metaphase from a sample with a 16p11.2 
duplication in which FISH signals appear to be stronger on one chromo-
some 16 (arrows) than on the other chromosome 16 (arrowhead).
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tion (as might well be expected from an allele 
that increases the risk of autism by as much as 
a factor of 100), given how often it arises de 
novo in a single generation.
Although multiplex families are expected to 
have fewer causal de novo mutations (and these 
do not contribute to the heritability of the disor-
der, except in cases arising from germ-line mosa-
icism  or  in  monozygotic  twins),  the  size  and 
resolution of this study have enabled the identifi-
cation of a recurrent de novo event that has a 
major effect in autism. Our observation of the 
same  event  at  very  low  prevalence  in  control 
samples and enriched in samples from Icelandic 
subjects with a psychiatric or language disorder 
suggests that rather than having 100% mendelian 
penetrance for a strictly defined form of autism, 
this region resembles other microdeletion or du-
plication  syndromes  that  are  high-penetrance 
causes of developmental abnormalities but show 
a range of phenotypic severity across entire popu-
lations. The four AGRE families whose members 
had deletions had three affected children without 
this event, which suggests intrafamilial heteroge-
neity within some multiplex families with autism, 
a finding that is not unexpected given the high 
rate of autism spectrum disorder.
Neither the specific deletion nor duplication 
of this region was found in the Autism Chromo-
some  Rearrangement  Database  (http://projects.
tcag.ca/autism).  In  independently  published 
studies, one observation of this microdeletion 
on 16p11.2 was made in a patient with autism6 
and  in  an  adult  twin  pair  with  multiple  con-
genital anomalies, including mild developmen-
tal delay.13 Another recent study14 showed the 
association between a larger microdeletion on 
16p and a syndrome that included developmen-
tal delay, distinct facial appearance, and other 
variable features. In this study, four deletions are 
described, three of which are adjacent to, but do 
not appear to overlap with, the 16p11.2 deletion; 
the fourth deletion is even larger and encom-
passes the 16p11.2 deletion. Additional case re-
ports of deletions on 16p11.2 with undetermined 
boundaries included a de novo deletion in a neo-
nate with multiple congenital malformations15 
and a deletion of unknown inheritance in a fe-
male subject with mild mental retardation, se-
vere speech delay, and facial dysmorphism.16
In our study, duplication of the 16p11.2 re-
gion cosegregated with autism in two families 
(six of six affected offspring) and occurred as a 
de novo event in a third family. Duplication in 
this region was also observed in four clinical 
samples referred for diagnosis of developmental 
delay, although no autistic features were report-
ed in three of these subjects. A larger duplica-
tion including this region was reported in two 
patients  with  autistic  behavior  and  cognitive 
impairment.17 We observed this duplication in 
none of the additional 2814 samples that were 
screened and at a very low rate in the Icelandic 
population,  indicating  that  duplication  of  the 
same region similarly influences susceptibility 
to developmental delay with variable features of 
autism and that one or more genes in the region 
may be particularly dosage sensitive (with sig-
nificant developmental manifestations when the 
region is either duplicated or deleted).
A comparison of our findings with those of 
other recent studies that have reported de novo 
copy-number variations in autism does not add 
compelling evidence in favor of susceptibility to 
autism conferred by other recently highlighted 
genomic regions. Furthermore, our data show little 
evidence of similar large, highly recurrent regions 
of de novo abnormality outside the 16p11.2 re-
gion and the frequently noted 15q11–13 duplica-
tions.
In conclusion, our data indicate that a region 
of chromosome 16p11.2 influences susceptibility 
to autism when it is either deleted or duplicated. 
Deletion and duplication events were observed 
in nearly 1% of multiplex families with autism, 
in 1% of subjects with autism in Iceland, and in 
more than 1.5% of clinical samples from sub-
jects with developmental delay. These events are 
either as frequent as or more frequent than the 
most common known cause of autism (duplica-
tion of the Prader–Willi/Angelman region), which 
is estimated to occur in 1% of subjects with au-
tism2 and was present in 0.35% of subjects in our 
sample. We detected no other recurrent events of 
note, which suggests that large de novo copy-
number mutations may explain only a fraction of 
familial idiopathic autism.
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